MDST Medicsight

RNS Number:0301S
Medicsight Plc
10 April 2008


Press Release                                                   10 April 2008


                                 Medicsight PLC

                        ("Medicsight" or "the Company")

              Chinese State Food and Drug Administration approval


Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, today announces that it has received approval from the
Chinese State Food and Drug Administration ("SFDA") for its MedicRead Colon
workstation.  Medicsight will launch this workstation via a Chinese dealer
network which gives the Company access to almost 1000 sales representatives.

David Sumner, Chief Executive of Medicsight, commented: "This is another
significant milestone for Medicsight and we are delighted to have received
approval from the SFDA.  China is one of the world's fastest growing medical
imaging markets and is one of Medicsight's core target markets, with a high
installed base of MDCT (Multidetector Computed Tomography), high incidence of
colorectal cancer and a large population.  In readiness for this approval,
Medicsight has been working closely with its Chinese dealer network in
preparation for the national launch in Guangzhou during the May Chinese Society
of Abdominal Radiology congress."

President Qi Ji, President of the Chinese Society of Radiology, said "We have
been working with Medicsight for 3 years as part of their Chinese clinical
programme.  We have been delighted with the performance of Medicsight's
products, which have proven to make a marked difference in the speed and
accuracy of our diagnosis.  As the number of patients in China increases, CAD
software is becoming increasingly important for radiologists where improved
workflow and productivity support their efforts to save lives.  I am delighted
that Medicsight's products will now be available to radiologists across China."

MedicRead Colon is an advanced visualisation workstation for CT Colonography and
combines Medicsight's ColonCAD computer-aided detection technology with 3D
imaging tools to assist radiologists in the detection of colorectal neoplasia
(polyps).  This software reduces the workload of radiologists by automatically
highlighting suspicious areas on scan images, and may also help radiologists
detect possibly malignant tumours at an early stage when treatment is most
likely to be successful.





                                    - ENDS -



For further information:

Medicsight PLC
David Sumner                                            Tel: +44 (0)20 7605 7950
                                                        www.medicsight.com
Collins Stewart Europe Limited
Tim Mickley                                             Tel: +44 (0)20 7523 8350
                                                        Tel: +44 (0)20 7523 8302

Media enquiries:
Abchurch                                               Tel: +44 (0) 20 7398 7700
Ashley Tapp                                            Tel: +44 (0) 20 7398 7718
ashley.tapp@abchurch-group.com
Stephanie Cuthbert                                     Tel: +44 (0) 20 7398 7712
stephanie.cuthbert@abchurch-group.com                  www.abchurch-group.com



Notes to editors

About Medicsight

Medicsight PLC is a UK-headquartered, research-driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCADTM and LungCADTM software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.



About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.



About Medicsight's CAD software

Medicsight's ColonCADTM and LungCADTM software use an advanced CAD algorithm to
analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.



Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.



Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCVKLFBVZBLBBV

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024